Home
FATE
FATE News

Latest Fate Therapeutics Inc. (FATE) News on August 24, 2025

Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data

Insider Monkey

a month ago

Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data

OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

PR Newswire

a month ago

OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Simply Wall St.

a month ago

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully

Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?

Zacks

2 months ago

Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

GlobeNewswire

2 months ago

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

Top Cancer Stocks to Supercharge Your 2025 Portfolio

Zacks

2 months ago

Top Cancer Stocks to Supercharge Your 2025 Portfolio

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

GlobeNewswire

3 months ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases

Insider Monkey

3 months ago

Fate Therapeutics, Inc. (FATE) Highlights Next-Gen iPSC Therapies for Autoimmune Diseases

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

GlobeNewswire

3 months ago

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

Fate Therapeutics First Quarter 2025 Earnings: Beats Expectations

Simply Wall St.

3 months ago

Fate Therapeutics First Quarter 2025 Earnings: Beats Expectations

Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus

Zacks

3 months ago

Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Zacks

3 months ago

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

GlobeNewswire

3 months ago

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

GlobeNewswire

4 months ago

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Recent uptick might appease Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners after losing 66% over the past year

Simply Wall St.

4 months ago

Recent uptick might appease Fate Therapeutics, Inc. (NASDAQ:FATE) institutional owners after losing 66% over the past year

Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

Zacks

4 months ago

Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

MT Newswires

4 months ago

Fate Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy Designation for Lupus Cell Therapy; Shares Fall

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

GlobeNewswire

4 months ago

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound?

Zacks

5 months ago

Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound?

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target

Simply Wall St.

6 months ago

Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target

FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus

Zacks

6 months ago

FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

Zacks

6 months ago

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

Associated Press Finance

6 months ago

Fate Therapeutics: Q4 Earnings Snapshot

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

GlobeNewswire

6 months ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

6 months ago

NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know

Zacks

6 months ago

Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know

Fate Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

6 months ago

Fate Therapeutics to Present at Upcoming Investor Conferences

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Simply Wall St.

7 months ago

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?

Zacks

8 months ago

Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?

MT Newswires

8 months ago

Fate Therapeutics Reports FT819 Shows 'Favorable Safety Profile,' Clinical Benefits

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

GlobeNewswire

8 months ago

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics makes Bob Valamehr president and CEO

Pharmaceutical Technology

9 months ago

Fate Therapeutics makes Bob Valamehr president and CEO

Fate Therapeutics Announces Leadership Transition

GlobeNewswire

9 months ago

Fate Therapeutics Announces Leadership Transition

Fate Therapeutics to Present at Upcoming December Investor Conferences

GlobeNewswire

9 months ago

Fate Therapeutics to Present at Upcoming December Investor Conferences

MT Newswires

9 months ago

BofA Securities Upgrades Fate Therapeutics to Neutral From Underperform, $3 Price Target

MT Newswires

9 months ago

Fate Therapeutics Shares Rise After 'Promising' Lupus Treatment Results

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

GlobeNewswire

9 months ago

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence

GlobeNewswire

9 months ago

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence

Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Simply Wall St.

9 months ago

Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

9 months ago

Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations

FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus

Zacks

9 months ago

FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus

Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates

Zacks

9 months ago

Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates

Associated Press Finance

9 months ago

Fate Therapeutics: Q3 Earnings Snapshot

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

GlobeNewswire

9 months ago

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

GlobeNewswire

9 months ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

MT Newswires

9 months ago

Fate Therapeutics Reports Positive Preclinical Data for Cancer Treatment Candidate

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

GlobeNewswire

9 months ago

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

10 months ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

GlobeNewswire

a year ago

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?

Zacks

a year ago

Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?

Broker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging Higher

Simply Wall St.

a year ago

Broker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging Higher

All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy

Zacks

a year ago

All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy

Fate Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

a year ago

Fate Therapeutics Second Quarter 2024 Earnings: Beats Expectations

FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow

Zacks

a year ago

FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Zacks

a year ago

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

MT Newswires

a year ago

Fate Therapeutics Q2 Loss Narrows, Revenue Rises

Associated Press Finance

a year ago

Fate Therapeutics: Q2 Earnings Snapshot

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

GlobeNewswire

a year ago

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Simply Wall St.

a year ago

Is Fate Therapeutics (NASDAQ:FATE) In A Good Position To Invest In Growth?

Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

GlobeNewswire

a year ago

Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

Motley Fool

a year ago

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a year ago

Piper Sandler Upgrades Fate Therapeutics to Overweight From Neutral, Adjusts Price Target to $6 From $4

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

GuruFocus.com

a year ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

Energy Global

a year ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

USA TODAY

a year ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Business Wire

a year ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Business Wire

a year ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

SEALSQ to Launch Two New Quantum Resistant Chips

GlobeNewswire

a year ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Reuters

a year ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

GlobeNewswire

a year ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

GlobeNewswire

a year ago

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript

Fate Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line

Simply Wall St.

a year ago

Fate Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line

GuruFocus.com

a year ago

Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial Performance Amid Clinical ...

MT Newswires

a year ago

Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating

MT Newswires

a year ago

Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Zacks

a year ago

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Associated Press Finance

a year ago

Fate Therapeutics: Q1 Earnings Snapshot

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

GlobeNewswire

a year ago

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

GlobeNewswire

a year ago

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates

GlobeNewswire

a year ago

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

GlobeNewswire

a year ago

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

GlobeNewswire

a year ago

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress

Zacks

a year ago

Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress

Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire

a year ago

Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?

Zacks

a year ago

Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?

Why Is Myriad (MYGN) Down 1% Since Last Earnings Report?

Zacks

a year ago

Why Is Myriad (MYGN) Down 1% Since Last Earnings Report?

Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?

Zacks

a year ago

Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

GlobeNewswire

a year ago

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Share on Social Networks: